A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms C-RESCUE
- 31 Jul 2017 Planned End Date changed from 15 Sep 2018 to 1 Feb 2018.
- 31 Jul 2017 Planned primary completion date changed from 15 Jun 2018 to 1 Dec 2017.
- 31 Jul 2017 Status changed from suspended to withdrawn prior to enrolment due to unavailability of investigational medication